Sana Biotechnology Announces Board and Executive Changes
Ticker: SANA · Form: 8-K · Filed: 2024-09-12T00:00:00.000Z
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
Related Tickers: SANA
TL;DR
Sana Bio (SANA) shakes up board & exec pay. Details light.
AI Summary
Sana Biotechnology, Inc. announced on September 6, 2024, changes related to its board of directors and executive compensation. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its officers. The filing does not specify the names of departing individuals or the exact nature of the compensatory changes.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence.
Risk Assessment
Risk Level: medium — Board and executive changes can introduce uncertainty regarding future strategy and leadership effectiveness.
Key Players & Entities
- Sana Biotechnology, Inc. (company) — Registrant
- September 6, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Seattle, Washington (location) — Principal executive offices
FAQ
What specific roles did the departing directors or officers hold?
The filing states the "Departure of Directors or Certain Officers" but does not specify the names or roles of the individuals involved.
Who were the newly elected directors?
The filing indicates the "Election of Directors" but does not list the names of the newly elected individuals.
What are the details of the updated compensatory arrangements for officers?
The filing mentions "Compensatory Arrangements of Certain Officers" but does not provide specific details on the changes made.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 6, 2024.
What is Sana Biotechnology, Inc.'s principal executive office address?
The principal executive offices are located at 188 East Blaine Street, Suite 400, Seattle, Washington 98102.
Filing Stats: 428 words · 2 min read · ~1 pages · Grade level 13 · Accepted 2024-09-12 16:36:55
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SANA The Nasdaq
Filing Documents
- d852081d8k.htm (8-K) — 21KB
- 0001193125-24-218049.txt ( ) — 143KB
- sana-20240906.xsd (EX-101.SCH) — 3KB
- sana-20240906_lab.xml (EX-101.LAB) — 18KB
- sana-20240906_pre.xml (EX-101.PRE) — 11KB
- d852081d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Sana Biotechnology, Inc. Date: September 12, 2024 By: /s/ Bernard J. Cassidy Bernard J. Cassidy Executive Vice President and General Counsel